Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase II Study of the Addition of Opaganib to Androgen Antagonists in Patients with Prostate Cancer Progression on Enzalutamide or Abiraterone
NCT Number:
NCT04207255
Phase:
II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Prostate
Study Objectives:
This is a Phase II efficacy study of opaganib in patients with metastatic castration-resistant prostate cancer (mCRPC) that is progressing during treatment with androgen signaling blockers abiraterone or enzalutamide.
Study Documents
(MUSC NetID required for document access)